Price T Rowe Associates Inc Eye Point Pharmaceuticals, Inc. Transaction History
Price T Rowe Associates Inc
- $816 Billion
- Q1 2024
A detailed history of Price T Rowe Associates Inc transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 2,465,815 shares of EYPT stock, worth $20.4 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,465,815
Previous 2,522,704
2.26%
Holding current value
$20.4 Million
Previous $58.3 Million
12.57%
% of portfolio
0.01%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding EYPT
# of Institutions
176Shares Held
53.9MCall Options Held
764KPut Options Held
1.57M-
Cormorant Asset Management, LP Boston, MA6.89MShares$56.9 Million8.2% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA4.76MShares$39.3 Million0.19% of portfolio
-
Suvretta Capital Management, LLC New York, NY3.76MShares$31.1 Million3.33% of portfolio
-
Franklin Resources Inc San Mateo, CA3.39MShares$28 Million0.02% of portfolio
-
Black Rock Inc. New York, NY2.79MShares$23 Million0.0% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $281M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...